GHK-Cu Peptide: Mechanisms, Evidence, and Clinical Applications

Sometime in the early 1970s, a biochemist named Loren Pickart noticed something puzzling. When old liver tissue was placed in the same culture medium as young liver tissue, the old cells began behaving younger. The signal responsible, he eventually determined, was a tiny tripeptide called GHK, glycyl-L-histidyl-L-lysine, naturally bound to copper. That molecule, now known as the GHK-Cu peptide, has since become one of the most studied compounds at the intersection of regenerative biology and longevity science. Decades of research have mapped its roles in wound healing, skin remodeling, hair follicle biology, and gene expression regulation, yet it remains poorly understood by most clinicians and almost entirely absent from mainstream conversations about healthy aging.

The GHK-Cu peptide is not a growth factor. It is not a hormone. It is a tripeptide, three amino acids long, that naturally circulates in human plasma at concentrations around 200 nanograms per milliliter at age 20, but drops to roughly 80 nanograms per milliliter by age 60. [1] That decline of more than 60 percent over four decades tracks closely with the deterioration of skin elasticity, wound repair capacity, and hair follicle cycling that characterize biological aging. Whether GHK-Cu is merely a biomarker of tissue health or an active driver of regeneration has been the central question guiding the field for fifty years. The evidence increasingly points toward the latter, and the mechanisms explaining how are becoming clearer.

GHK-Cu plasma levels fall by more than 60 percent between age 20 and age 60, tracking closely with the loss of skin elasticity, wound repair capacity, and follicular cycling that define biological aging.

What GHK-Cu Actually Is

Understanding why GHK-Cu does what it does requires understanding what it is at the chemical level. Glycyl-L-histidyl-L-lysine is a naturally occurring tripeptide fragment derived from the breakdown of larger proteins, most likely collagen and albumin. Its remarkable property is an extremely high affinity for copper (II) ions, forming a stable 1:1 complex that gives the molecule its characteristic blue-green color and much of its biological activity. [1] Copper is not a passenger here. The metal ion fundamentally changes the peptide's conformation and dramatically expands its range of biological interactions.

In plasma, GHK-Cu exists as part of a broader copper transport system. Ceruloplasmin and albumin handle most systemic copper delivery, but GHK appears to act as a local tissue copper chaperone, capturing free copper ions that become available during protein breakdown and ferrying them safely to cells that need them for enzymatic processes. Free copper is highly toxic to cells because it catalyzes the Fenton reaction, a chain of oxidative chemistry that shreds lipid membranes and DNA. GHK-Cu essentially performs cellular fire suppression, neutralizing dangerous free copper while simultaneously delivering a usable form of the mineral to receptors and enzymes that depend on it.

The peptide enters cells through a mechanism that is still being characterized, but current evidence suggests it interacts with cell surface receptors and activates downstream signaling cascades without being fully internalized in all tissue types. [2] In other contexts, particularly in keratinocytes and fibroblasts, it appears to enter the cell directly and traffic to the nucleus, where its effects on gene expression become most apparent. This dual mode of action, surface receptor activation and intracellular nuclear signaling, helps explain the remarkable breadth of physiological responses the molecule can trigger.

The Gene Expression Story

Perhaps the most striking chapter in GHK-Cu research opened in 2010, when Pickart and colleagues analyzed publicly available gene expression datasets and found that GHK-Cu modulates the expression of over 4,000 human genes, approximately one-third of all known gene networks. [1] That number deserves a moment of reflection. Most pharmaceuticals target a single receptor or enzyme. GHK-Cu, a molecule three amino acids long, appears to reorganize the activity of thousands of genes simultaneously.

The pattern of those changes is what makes the finding biologically coherent rather than simply overwhelming. GHK-Cu tends to upregulate genes associated with collagen synthesis, antioxidant defense, DNA repair, and anti-inflammatory signaling. Simultaneously, it downregulates genes associated with inflammation, oxidative stress, cancer progression, and tissue breakdown. The net effect, at the transcriptome level, resembles a reversal of the gene expression signature associated with aging. [1] This is not metaphorical. When researchers map the gene expression changes induced by GHK-Cu against known aging signatures, the two profiles are essentially mirror images of each other.

At the transcriptome level, the gene expression changes induced by GHK-Cu resemble a systematic reversal of the aging signature, upregulating repair and anti-inflammatory genes while silencing those driving tissue breakdown.

The mechanism underlying this broad transcriptional regulation likely involves multiple pathways. GHK-Cu has been shown to activate the transcription factor SP1, inhibit NF-kB (the master switch for inflammatory gene expression), and modulate the activity of histone deacetylases, enzymes that control how tightly DNA is wound around histone proteins. [2] That last mechanism places GHK-Cu squarely in the emerging science of epigenetic reprogramming, the idea that aging is not just about accumulated DNA damage but about dysfunctional gene expression patterns that can, in principle, be corrected. Understanding this epigenetic dimension makes the peptide's downstream tissue effects far less surprising.

Skin Biology: Collagen, Elastin, and the Architecture of Youth

Skin aging is fundamentally a structural problem. The dermis, the deep layer of skin beneath the visible surface, is a dense scaffolding of collagen and elastin fibers produced by fibroblast cells. Young skin has a scaffold that is dense, organized, and continuously renewed. Aged skin has a scaffold that is fragmented, cross-linked in dysfunctional ways, and no longer adequately maintained because fibroblast activity declines with age and the inflammatory environment of aging tissue accelerates matrix breakdown faster than repair can keep pace. GHK-Cu addresses this problem at multiple levels simultaneously.

Studies going back to the 1980s demonstrated that GHK-Cu stimulates fibroblasts to increase production of collagen type I, type III, and type IV, as well as glycosaminoglycans like hyaluronic acid and dermatan sulfate, which form the gel-like ground substance of the dermis. [1] More recently, GHK-Cu has been shown to upregulate the expression of metalloproteinases that selectively break down damaged or cross-linked collagen while simultaneously stimulating synthesis of new collagen. This dual action, controlled demolition paired with construction, is more sophisticated than simply flooding the dermis with new collagen. It reorganizes and refines the scaffold rather than merely adding mass.

In a double-blind, placebo-controlled study of 67 women with mild to moderate facial photodamage, a topical cream containing GHK-Cu produced statistically significant improvements in skin laxity, clarity, and firmness over 12 weeks. [3] Ultrasound imaging of the dermis confirmed a measurable increase in skin density in the treated group that was not seen in controls. The effects were comparable to those seen with well-established retinoid compounds, without the irritation and photosensitivity that retinoids typically produce. A separate controlled trial found that GHK-Cu peptide eye cream reduced fine lines and improved overall periorbital skin quality significantly compared to placebo over the same timeframe. [3]

The antioxidant dimension of GHK-Cu activity in skin is equally important. Ultraviolet radiation generates reactive oxygen species that oxidize lipids and proteins in the dermis, and GHK-Cu has been shown to upregulate superoxide dismutase and catalase, two of the cell's primary antioxidant enzymes, while also directly chelating free copper and iron ions that would otherwise catalyze oxidative damage. [2] The net result is a tissue environment in which oxidative damage proceeds more slowly, giving repair mechanisms a chance to keep pace. For anyone thinking about skin aging in terms of healthspan rather than mere cosmetics, this represents a meaningful biological intervention.

Wound Healing: From Battlefields to Surgical Suites

Wound healing was where GHK-Cu first demonstrated clinical utility, and the science here is more mature than in any other application. Cutaneous wound healing proceeds through three overlapping phases: inflammation, proliferation, and remodeling. Each phase depends on precise molecular signaling, and GHK-Cu has documented roles in all three. It attracts the macrophages and mast cells needed for the inflammatory phase, stimulates the keratinocyte migration and fibroblast proliferation that drive the proliferative phase, and promotes the organized collagen remodeling that determines scar quality in the final phase. [1]

Animal studies have shown that GHK-Cu significantly accelerates wound closure, increases tensile strength of healed tissue, and improves the appearance of resulting scars. [2] In diabetic animal models, where impaired wound healing is a major complication, GHK-Cu restored healing rates close to those of non-diabetic controls, a finding with obvious clinical implications given that chronic wounds represent one of the most costly and debilitating sequelae of diabetes. The mechanism in the diabetic context appears to involve restoration of angiogenesis, the growth of new capillaries, which is severely impaired in diabetic tissue. GHK-Cu upregulates vascular endothelial growth factor (VEGF) and its receptors, effectively re-igniting the capillary growth that the metabolic environment of diabetes had suppressed.

Topical GHK-Cu has been incorporated into wound care preparations in clinical settings for decades, particularly in the management of post-surgical wounds and chronic ulcers, and its safety profile is well established across this literature. The translation from animal models to human wounds is supported by the mechanistic consistency of the data, though large randomized controlled trials in humans specifically examining wound closure endpoints remain limited. This is an honest appraisal of the evidence: the mechanistic rationale is strong, the preclinical data is compelling, and the human safety data is reassuring, but the gold-standard human efficacy trials in wound healing are fewer than one would like.

Hair Follicle Biology and the Case for GHK-Cu

Hair loss, or alopecia, is among the most psychologically significant manifestations of aging, and the biology underlying it overlaps substantially with the broader biology GHK-Cu is known to modulate. Hair follicles cycle through phases of growth (anagen), regression (catagen), and rest (telogen). In androgenetic alopecia, the most common form of age-related hair loss, follicles progressively miniaturize across repeated cycles, producing thinner and shorter hairs until the follicle eventually becomes dormant. The microenvironment of the aging scalp, characterized by chronic low-grade inflammation, oxidative stress, and reduced blood flow to follicle dermal papilla cells, drives this miniaturization process.

GHK-Cu acts on hair follicle biology through several converging pathways. It has been shown to enlarge the size of hair follicles in animal models, prolong the anagen growth phase, and stimulate the proliferation of dermal papilla cells, the specialized fibroblast-like cells at the base of each follicle that control follicle cycling. [2] In a controlled study applying GHK-Cu to the scalp of individuals with thinning hair, treated subjects showed a significant increase in hair density and diameter compared to controls after 12 weeks of twice-daily topical application. The anti-inflammatory and pro-angiogenic properties of GHK-Cu are likely central to these effects, since follicle miniaturization is driven in part by perifollicular inflammation and ischemia, exactly the conditions GHK-Cu is equipped to counter.

It is worth noting that GHK-Cu is not the only topical intervention showing promise for follicle-focused longevity. Topical Rapamycin+ for Hair operates through a mechanistically distinct pathway, inhibiting mTOR signaling in follicle cells to reduce senescence and extend anagen duration, and the two approaches may be complementary rather than competing. The field of follicle biology is gradually assembling a toolkit of interventions that target different nodes of the same aging process, and GHK-Cu represents one of the better-characterized components of that toolkit.

Systemic and Longevity Effects: Beyond the Skin

The gene expression data positions GHK-Cu as a molecule with potential systemic longevity effects that extend well beyond its topical applications, and several lines of research have begun to explore this territory. One of the most intriguing involves the peptide's effects on inflammation. Chronic low-grade inflammation, now commonly termed "inflammaging," is recognized as a root driver of virtually every major age-related disease, from cardiovascular disease to neurodegeneration to cancer. GHK-Cu's consistent downregulation of NF-kB activity and pro-inflammatory cytokines like TNF-alpha and IL-6 positions it as a potential systemic anti-inflammatory agent when administered via routes that achieve meaningful plasma concentrations. [1]

In the context of cancer biology, GHK-Cu presents a particularly nuanced picture. Pickart's gene expression analyses identified GHK-Cu as one of the few naturally occurring compounds that reverses the gene expression signature of aggressive metastatic cancers toward a more differentiated, less malignant phenotype. [1] Genes that drive epithelial-to-mesenchymal transition, the process by which cancer cells acquire the ability to invade and metastasize, are among those downregulated by GHK-Cu treatment in cell culture and animal models. This is early-stage evidence and should not be interpreted as a cancer treatment, but it adds to the picture of a molecule that is doing something fundamental at the level of cellular identity and behavior.

GHK-Cu also activates superoxide dismutase (SOD) and catalase at the systemic level, and has been shown to protect neurons from oxidative stress in cell culture models of neurodegenerative disease. [2] Its copper-carrying function is directly relevant here. Copper-zinc superoxide dismutase (SOD1) is one of the cell's primary defenses against free radical damage, and it depends on adequate copper delivery to function. In aged tissue, dysregulated copper metabolism is a consistent finding, and GHK-Cu's role as a copper chaperone may help restore SOD1 activity in cells where copper availability had become limiting.

The peptide's potential effects on lung tissue deserve specific mention. Multiple studies have examined GHK-Cu's activity in pulmonary fibroblasts, where it has been shown to inhibit the TGF-beta-driven fibrotic signaling that underlies conditions like idiopathic pulmonary fibrosis. [1] Given that pulmonary function declines measurably with age and that lung fibrosis is among the most feared outcomes of age-related lung injury, these findings suggest a potential application of GHK-Cu that goes substantially beyond aesthetics.

Delivery Methods: Injection vs. Topical vs. Intranasal

The route of GHK-Cu administration is not a trivial clinical question. It determines which tissues are reached, at what concentrations, and for how long, and the evidence supporting different applications comes from studies using different delivery routes. Understanding these distinctions is essential for anyone evaluating the clinical literature or considering therapeutic use.

Topical application is the most widely studied and clinically validated delivery route. When formulated in appropriate vehicles, GHK-Cu penetrates the stratum corneum, the outermost barrier layer of skin, and reaches fibroblasts in the dermis at concentrations sufficient to elicit the collagen synthesis, antioxidant, and anti-inflammatory effects documented in clinical trials. [3] Penetration efficiency depends heavily on formulation: liposomal or nanoparticle encapsulation substantially improves dermal delivery compared to aqueous solutions. The molecular size of GHK-Cu, at approximately 340 daltons, is below the 500-dalton threshold generally considered the cutoff for percutaneous absorption, which favors topical delivery relative to larger peptides. Concentrations used in validated studies typically range from 0.05 percent to 1 percent in topical formulations, applied once or twice daily.

Subcutaneous injection bypasses the skin barrier entirely and delivers GHK-Cu directly into the systemic circulation, potentially achieving the kind of plasma concentrations that would be necessary to produce systemic effects on gene expression, inflammation, and tissue biology beyond the skin. Injectable GHK-Cu is available through compounding pharmacies in concentrations typically ranging from 200 to 500 micrograms per milliliter, and protocols in clinical use generally involve doses between 1 and 3 milligrams per injection, administered two to five times per week. The pharmacokinetics of injected GHK-Cu have not been rigorously characterized in published human trials, which is a significant limitation. The peptide is small and likely cleared relatively quickly from circulation, which has implications for dosing frequency. Clinical supervision is essential when considering injectable peptide protocols: the same pharmacological activity that makes GHK-Cu interesting also means that unsupervised self-administration carries meaningful risks, including infection at injection sites and unpredictable interactions in individuals with complex medical histories.

Intranasal delivery represents an emerging and theoretically interesting third route, particularly for potential neurological applications. The olfactory pathway provides a direct anatomical connection between the nasal mucosa and the brain, bypassing the blood-brain barrier, and small peptides delivered intranasally can reach cerebrospinal fluid and brain tissue at meaningful concentrations. This is the rationale behind intranasal delivery of other neuropeptides, and it has been proposed for GHK-Cu in the context of neuroprotection, though published human data for this route are lacking. The interest here is not frivolous, given GHK-Cu's demonstrated neuroprotective effects in cell culture and its copper-chaperone function relevant to superoxide dismutase activity in neural tissue, but it should be clearly categorized as speculative in terms of human clinical evidence.

Dosing Protocols: What the Evidence Supports

Synthesizing the dosing literature requires distinguishing carefully between what has been tested in controlled trials and what represents clinical practice consensus in the absence of definitive trial data. For topical applications, the controlled trial evidence supports concentrations between 0.1 percent and 1 percent GHK-Cu in appropriate carrier formulations, applied once or twice daily to the target tissue. The 12-week trial by Leyden and colleagues used 1 percent GHK-Cu and found statistically significant improvements in skin density and appearance. [3] Twice-daily application appeared in both the skin and hair studies that showed positive results, suggesting that frequency matters for topical delivery, likely because the peptide is metabolized relatively quickly once it penetrates the skin.

For scalp application targeting hair follicle biology, the protocol used in published studies involved twice-daily application of a GHK-Cu-containing solution massaged into the scalp for at least 60 seconds to encourage penetration, continued for 12 to 16 weeks before assessing response. Maintenance protocols following an initial response phase have not been formally characterized in trials but logically resemble the induction protocol at reduced frequency.

For injectable GHK-Cu, no formally published human dose-finding trials exist. Protocols circulating in clinical and functional medicine communities typically involve 1 to 3 milligrams per injection, administered subcutaneously two to three times per week, for cycles of four to twelve weeks. These doses are extrapolated from animal study data and the known endogenous plasma concentrations of GHK-Cu in young adults, not from human pharmacokinetic studies. This distinction matters enormously. The absence of rigorous human dose-finding data means that practitioners and patients are operating in a region of genuine uncertainty, and the responsible clinical stance is to start conservatively, monitor for adverse effects, and not extrapolate from the safety record of topical applications to the injectable route. A program like Healthspan's Longevity Optimization program provides the clinical framework for evaluating whether peptide therapy fits within an individual's broader biology and health goals.

Cycling protocols, periods of active peptide use alternating with washout periods, are theoretically motivated by concerns about receptor desensitization and the general principle that many biological signaling interventions work better when the system retains some dynamic range. In the absence of human data specifically addressing receptor downregulation for GHK-Cu, cycling is a reasonable precaution rather than an evidence-based requirement. Common clinical practice involves four to eight week cycles of injectable GHK-Cu followed by two to four week breaks.

Safety Profile and Known Limitations

GHK-Cu has an unusually favorable safety profile given the breadth of its biological activity. Topical applications have been tested in multiple controlled clinical trials without significant adverse effects beyond occasional mild skin irritation at high concentrations. [3] The molecule is naturally present in human plasma and tissues, metabolized via standard proteolytic pathways, and does not accumulate in organs. No teratogenic or genotoxic effects have been identified in the published literature.

The copper component of GHK-Cu warrants attention because copper toxicity is a real clinical entity. However, the amounts of copper delivered via standard GHK-Cu protocols are orders of magnitude below the threshold associated with toxicity. A typical 2-milligram dose of GHK-Cu contains approximately 0.3 micrograms of copper, compared to a dietary daily intake of 900 to 1300 micrograms considered adequate for adults. The copper in GHK-Cu is also complexed and therefore far less bioavailable as free copper than dietary copper. [2] That said, individuals with Wilson's disease or other copper metabolism disorders should not use GHK-Cu without specialist guidance.

The most significant limitation of the GHK-Cu literature is not safety but efficacy evidence quality. Many of the most striking findings come from in vitro cell culture studies or animal models, and the human clinical trial database is thinner than one would expect for a molecule with fifty years of research behind it. The skin aging trials are the best characterized, followed by wound healing data (much of which is preclinical), followed by hair biology data (limited human trials), followed by systemic longevity effects (largely mechanistic and inferential). Anyone integrating GHK-Cu into a longevity protocol should understand this evidence hierarchy and calibrate expectations accordingly. The mechanistic case is strong. The human clinical case, particularly for systemic applications, is promising but incomplete.

Compounding quality is a practical concern specific to the injectable route. Peptides compounded for injection must be sterile, correctly dosed, and free of endotoxins. These quality parameters vary across compounding pharmacies and cannot be verified without independent laboratory testing. Sourcing injectable peptides through a licensed telehealth or clinical provider, rather than from unregulated online sources, is not optional from a safety standpoint. The Longevity Pro Panel provides the kind of comprehensive baseline biomarker assessment that allows clinicians to evaluate tissue biology before and during any peptide protocol, turning what would otherwise be a blind intervention into a measurable one.

GHK-Cu in the Context of a Longevity Protocol

No single molecule reverses aging. GHK-Cu is interesting precisely because it operates at a systems level, modulating thousands of genes, replenishing a copper-chaperone function that declines with age, and addressing multiple convergent mechanisms of tissue aging simultaneously. But understanding where it fits in a broader longevity framework requires situating it alongside the other interventions that address overlapping biological targets.

The cellular senescence pathway, targeted by compounds like rapamycin, and the autophagy axis, central to how cells clear damaged components, both intersect with the biology GHK-Cu modulates. Cellular senescent cells accumulate in aged tissue and secrete inflammatory cytokines (the so-called senescence-associated secretory phenotype, or SASP) that create exactly the kind of inflammatory microenvironment that GHK-Cu's anti-inflammatory gene expression changes work to counteract. [2] In principle, combining a senolytic approach through The Rapamycin Protocol with the anti-inflammatory and regenerative activity of GHK-Cu could address the aging tissue problem from two complementary angles: reducing the burden of senescent cells while simultaneously promoting the repair and regenerative activity of the remaining healthy cells. This is a mechanistically coherent combination, though it has not been tested in controlled human trials.

The skin-specific longevity angle also benefits from thinking about hormonal context. Estrogen receptors are expressed throughout the dermis, and estrogen deficiency after menopause is one of the most potent accelerators of skin aging, reducing collagen content by approximately 30 percent in the first five years after menopause. [1] For postmenopausal women, restoring estrogen levels through therapies like the Estradiol Patch or Bi-Est 50/50 Cream addresses a foundational driver of skin aging that GHK-Cu alone cannot replace. The two approaches are synergistic: hormonal restoration rebuilds the hormonal context in which dermal fibroblasts operate optimally, while GHK-Cu provides additional direct stimulation of collagen synthesis and matrix remodeling within that restored context. Similarly, for men experiencing age-related testosterone decline, the dermal effects of testosterone deprivation, including thinning skin and impaired wound healing, represent another foundational driver that GHK-Cu's topical activity cannot fully substitute for.

Inflammation management is a third point of intersection. Chronic systemic inflammation accelerates every tissue aging process that GHK-Cu addresses locally. Interventions that reduce systemic inflammatory burden, including dietary approaches, exercise, and metabolic optimization via agents like metformin, create a more favorable tissue environment in which the regenerative signals from GHK-Cu can produce their full effects. The peptide is not a substitute for addressing root causes of inflammaging. It is most rationally used as one layer of a coordinated protocol, not as a standalone solution.

The Road Ahead: What Research Needs to Establish

The GHK-Cu field needs several things to mature into a clinical discipline rather than a collection of promising findings. First, properly powered randomized controlled trials of injectable GHK-Cu in humans, with pre-specified endpoints across multiple tissue systems, are essential. The skin aging trials provide a model, and the infrastructure for such trials now exists. Second, human pharmacokinetic studies characterizing the half-life, tissue distribution, and dose-response relationships of administered GHK-Cu are a prerequisite for rational dosing, and their absence is a significant gap. Third, long-term safety data for injectable protocols, which are now used by substantial numbers of individuals through functional medicine practitioners, should be systematically collected and published.

The gene expression data is perhaps the most compelling long-term research direction. If GHK-Cu genuinely modulates the expression of 4,000 genes in a pattern that recapitulates a younger transcriptional state, that is not just a pharmaceutical curiosity. It is a potential window into epigenetic reprogramming of aging tissue at a level of sophistication that no existing drug approaches. [1] Validating that finding in vivo in humans, characterizing which tissues respond most strongly, and determining what dose and duration of exposure is needed to produce durable transcriptional changes are questions that could shape the next decade of longevity medicine.

The decline of endogenous GHK-Cu with age raises the most fundamental question: is restoring youthful GHK-Cu levels sufficient to meaningfully slow or reverse the tissue aging process in those systems where GHK-Cu is a limiting factor? The honest answer is that no one yet knows. The mechanistic evidence says it should. The preclinical evidence says it can. The human clinical evidence says it does something, particularly in skin. Whether it does enough, in the right tissues, and with the right delivery methods to meaningfully extend healthspan in a human lifetime is the question that the next generation of GHK-Cu research must answer.

Conclusion

Fifty years after Loren Pickart first noticed that a tiny molecule was making old liver cells behave young, GHK-Cu sits at a genuinely interesting junction in longevity science. It is not experimental in the sense of untested: decades of research have mapped its mechanisms with unusual precision, and clinical trials have validated its topical effects on skin aging with rigor comparable to established cosmeceutical compounds. But neither is it established in the sense that most clinicians would recognize it as a standard-of-care intervention. It occupies the productive middle ground where mechanistic understanding is strong, early clinical evidence is encouraging, and the hard work of definitive human trials remains largely ahead.

What makes GHK-Cu worth taking seriously in a longevity context is not any single application but the coherence of its mechanism with the biology of aging itself. A molecule that naturally declines in the bloodstream as tissues age, that modulates the transcription of thousands of genes in a pattern that reverses the aging signature, that replenishes a critical copper-chaperone function in the tissue microenvironment, and that has documented effects on collagen synthesis, inflammation, oxidative stress, wound healing, and follicle biology is not simply a cosmetic ingredient. It is a biological signal whose absence from the aging body may be consequential in ways the field is only beginning to quantify. The science of GHK-Cu is a reminder that some of the most important molecules in aging biology are not exotic pharmaceuticals but natural compounds whose endogenous decline we have only recently learned to measure and, potentially, to address.